SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines
Summary
SonoThera closed an oversubscribed $125 million Series B round to fund its ultrasound-mediated nonviral genetic medicine platform. The company will use the proceeds to move lead programs for Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease into the clinic. It also plans to expand its pipeline across multiple organ systems and further scale its RIPPLE and PORE technologies. The company expects to begin its first clinical trial in DMD in 2027.
Funding
Amount
$125.0M
Total raised
Date
June 10, 2026
Announcement date
Investors
Illumina Ventures, ARK Investment Management, Alexandria Venture Investments, Bayer, JPOD @ Philadelphia QuickFire Challenge, SymBiosis, UCB Ventures, Johnson & Johnson, Vida Ventures, Vivo Capital, Vertex Ventures HC, RA Capital Management
Lead investors
Company
sonothera.com
Funded company
Classifications
industries
Entertainment
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected